{"altmetric_id":2948666,"counts":{"readers":{"mendeley":15,"citeulike":0,"connotea":0},"total":{"posts_count":3},"twitter":{"unique_users_count":3,"unique_users":["philipcrobinson","drhectorchinoy","MRCCTU"],"posts_count":3}},"selected_quotes":["2nd-line agents in myositis: 1-yr trial of additional immunosuppression in patients w\/ partial response to steroids","Second line agents #myositis trial, MTX\/cic - no improvement in patients who had prior incomplete steroid response","Also, open access review on second line agents in #myositis #rheumedu"],"citation":{"abstract":"Ciclosporin and MTX are used in idiopathic inflammatory myopathies (DM and PM) when patients incompletely respond to glucocorticoids. Their effectiveness is unproved in randomized controlled trials (RCTs). We evaluated their benefits in a placebo-controlled factorial RCT.","abstract_source":"pubmed","altmetric_jid":"4f6fa5133cf058f610003499","authors":["Fowzia Ibrahim","Ernest Choy","Patrick Gordon","Caroline J. Dor\u00e9","Alan Hakim","George Kitas","David Isenberg","Bridget Griffiths","Bryan Lecky","Kuntal Chakravarty","John Winer","Katalin Danko","Robert G. Cooper","Beverley White-Alao","David L. Scott","Ibrahim F","Choy E","Gordon P","Dor\u00e9 CJ","Hakim A","Kitas G","Isenberg D","Griffiths B","Lecky B","Chakravarty K","Winer J","Danko K","Cooper RG","White-Alao B","Scott DL","F. Ibrahim","E. Choy","P. Gordon","C. J. Dore","A. Hakim","G. Kitas","D. Isenberg","B. Griffiths","B. Lecky","K. Chakravarty","J. Winer","K. Danko","R. G. Cooper","B. White-Alao","D. L. Scott"],"doi":"10.1093\/rheumatology\/keu442","endpage":"1055","first_seen_on":"2014-12-04T06:25:00+00:00","funders":["niehs","aruk","mrc"],"issns":["1462-0332","1462-0324"],"issue":"6","journal":"Rheumatology","last_mentioned_on":1444732918,"links":["http:\/\/rheumatology.oxfordjournals.org\/content\/early\/2014\/11\/27\/rheumatology.keu442.abstract?papetoc=","http:\/\/rheumatology.oxfordjournals.org\/content\/early\/2014\/11\/27\/rheumatology.keu442.long","http:\/\/rheumatology.oxfordjournals.org\/content\/54\/6\/1050.long"],"pdf_url":"http:\/\/rheumatology.oxfordjournals.org\/content\/early\/2014\/11\/27\/rheumatology.keu442.full.pdf","pmid":"25433040","pubdate":"2015-06-01T00:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"},{"name":"Immunology","scheme":"era"},{"name":"Public Health And Health Services","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"1050","subjects":["rheumatology"],"title":"Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids","type":"article","uri":"https:\/\/academic.oup.com\/rheumatology\/article-lookup\/doi\/10.1093\/rheumatology\/keu442","volume":"54","mendeley_url":"http:\/\/www.mendeley.com\/research\/secondline-agents-myositis-1year-factorial-trial-additional-immunosuppression-patients-partially-res"},"altmetric_score":{"score":1.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":1.5},"context_for_score":{"all":{"total_number_of_other_articles":6237522,"mean":5.9780720020044,"rank":2553858,"this_scored_higher_than_pct":56,"this_scored_higher_than":3546402,"rank_type":"exact","sample_size":6237522,"percentile":56},"similar_age_3m":{"total_number_of_other_articles":188504,"mean":7.973401325178,"rank":76711,"this_scored_higher_than_pct":56,"this_scored_higher_than":105976,"rank_type":"exact","sample_size":188504,"percentile":56},"this_journal":{"total_number_of_other_articles":1797,"mean":4.5745467706013,"rank":898,"this_scored_higher_than_pct":46,"this_scored_higher_than":831,"rank_type":"exact","sample_size":1797,"percentile":46},"similar_age_this_journal_3m":{"total_number_of_other_articles":36,"mean":7.6437714285714,"rank":16,"this_scored_higher_than_pct":50,"this_scored_higher_than":18,"rank_type":"exact","sample_size":36,"percentile":50}}},"demographics":{"poster_types":{"member_of_the_public":3},"users":{"twitter":{"cohorts":{"Members of the public":3}},"mendeley":{"by_status":{"Professor > Associate Professor":2,"Researcher":4,"Student  > Doctoral Student":1,"Student  > Ph. D. Student":2,"Student  > Postgraduate":1,"Student  > Master":1,"Other":1,"Student  > Bachelor":1,"Lecturer":1,"Lecturer > Senior Lecturer":1},"by_discipline":{"Medicine and Dentistry":12,"Immunology and Microbiology":1,"Unspecified":2}}},"geo":{"twitter":{"AU":1,"GB":2},"mendeley":{"GB":1}}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/philipcrobinson\/status\/540391186473578496","license":"datasift","citation_ids":[2948666],"posted_on":"2014-12-04T06:24:33+00:00","author":{"name":"Philip Robinson","url":"http:\/\/brisbanerheumatology.com.au","image":"https:\/\/pbs.twimg.com\/profile_images\/741158167237775360\/Umv4cQ26_normal.jpg","description":"Rheumatologist; tweet health, healthcare, medicine, science & rheumatology mostly.","id_on_source":"philipcrobinson","tweeter_id":"246959615","geo":{"lt":-27.46794,"ln":153.02809,"country":"AU"},"followers":2225},"tweet_id":"540391186473578496"},{"url":"https:\/\/twitter.com\/drhectorchinoy\/status\/540423912455016448","license":"datasift","citation_ids":[2948666],"posted_on":"2014-12-04T08:34:35+00:00","author":{"name":"Hector Chinoy","url":"http:\/\/www.manchester.ac.uk\/research\/hector.chinoy\/","image":"https:\/\/pbs.twimg.com\/profile_images\/611888278388768769\/KFkssZh7_normal.jpg","description":"Rheumatologist, University of Manchester\/Salford Royal, UK. Interests in Neuromuscular disease, myositis, running, Newcastle United, views my own!","id_on_source":"drhectorchinoy","tweeter_id":"250668257","geo":{"lt":53.48095,"ln":-2.23743,"country":"GB"},"followers":1731},"tweet_id":"540423912455016448"},{"url":"http:\/\/twitter.com\/MRCCTU\/statuses\/653883370498297856","license":"gnip","citation_ids":[2948666],"posted_on":"2015-10-13T10:41:58+00:00","author":{"name":"MRC CTU at UCL","url":"http:\/\/www.ctu.mrc.ac.uk","image":"https:\/\/pbs.twimg.com\/profile_images\/903630404711800833\/-YY_g6-t_normal.jpg","description":"The MRC Clinical Trials Unit @UCL works on answering internationally important questions in infectious diseases and  cancer, and improving trial methodology.","id_on_source":"MRCCTU","tweeter_id":"539894768","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":2001},"tweet_id":"653883370498297856"}]}}